Combination treatment with decitabine and ionizing radiation enhances tumor cells susceptibility of T cells

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Son, Cheol Hun ^a   Lee, Hong Rae ^a,b   Koh, Eun Kyoung ^a   Shin, Dong Yeok ^a   Bae, Jae Ho ^b   Yang, Kwangmo ^a   Park, You Soo ^a  

^a Dongnam Institute of Radiological and Medical Science   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84988808389     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep32470     Document Type: Article

References (46)

1. Issa, J. P. Decitabine. Curr Opin Oncol 15, 446-451 (2003).
2. Yoo, C. B., & Jones, P. A. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5, 37-50 (2006).
3. Oki, Y., Aoki, E., & Issa, J. P. Decitabine-bedside to bench. Crit Rev Oncol Hematol 61, 140-152 (2007).
4. Fonsatti, E., et al. Methylation-regulated expression of HLA class I antigens in melanoma. Int J Cancer 105, 430-431, author reply 432-433 (2003).
5. Fonsatti, E., et al. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-Aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res 13, 3333-3338 (2007).
6. Gasparollo, A., et al. Unbalanced expression of HLA-A and-B antigens: a specific feature of cutaneous melanoma and other nonhemopoietic malignancies reverted by IFN-gamma. Int J Cancer 91, 500-507 (2001).
7. Nie, Y., et al. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis 22, 1615-1623 (2001).
8. Zhou, J. H., et al. Demethylating agent decitabine induces autologous cancer testis antigen specific cytotoxic T lymphocytes in vivo. Chin Med J (Engl) 126, 4552-4556 (2013).
9. Kaminskas, E., et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11, 3604-3608 (2005).
10. Saleh, M. H., Wang, L., & Goldberg, M. S. Improving cancer immunotherapy with DNA methyltransferase inhibitors. Cancer Immunol Immunother 65, 787-796 (2015).
11. Triozzi, P. L., et al. Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice. Cancer Immunol Immunother 61, 1441-1450 (2012).
12. Schmiedel, B. J., et al. Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int J Cancer 128, 2911-2922 (2011).
13. Rohner, A., Langenkamp, U., Siegler, U., Kalberer, C. P., & Wodnar-Filipowicz, A. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk Res 31, 1393-1402 (2007).
14. Tang, K. F., et al. Induction of MHC class I-related chain B (MICB) by 5-Aza-2'-deoxycytidine. Biochem Biophys Res Commun 370, 578-583 (2008).
15. Raulet, D. H. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3, 781-790 (2003).
16. Lanier, L. L. NK cell recognition. Annu Rev Immunol 23, 225-274 (2005).
17. Kim, J. Y., et al. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp Mol Med 38, 474-484 (2006).
18. Bauer, S., et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727-729 (1999).
19. Baragano Raneros, A., et al. Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia. Genes Immun 16, 71-82 (2015).
20. Formenti, S. C., & Demaria, S. Systemic effects of local radiotherapy. Lancet Oncol 10, 718-726 (2009).
21. Larsson, M., Fonteneau, J. F., & Bhardwaj, N. Dendritic cells resurrect antigens from dead cells. Trends Immunol 22, 141-148 (2001).
22. Ishihara, H., Tsuneoka, K., Dimchev, A. B., & Shikita, M. Induction of the expression of the interleukin-1 beta gene in mouse spleen by ionizing radiation. Radiat Res 133, 321-326 (1993).
23. Hong, J. H., et al. Induction of acute phase gene expression by brain irradiation. Int J Radiat Oncol Biol Phys 33, 619-626 (1995).
24. Hong, J. H., et al. Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int J Radiat Biol 75, 1421-1427 (1999).
25. Friedman, E. J. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 8, 1765-1780 (2002).
26. Moretta, A., et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 14, 619-648 (1996).
27. Gao, X. N., Lin, J., Wang, L. L., & Yu, L. Demethylating treatment suppresses natural killer cell cytolytic activity. Mol Immunol 46, 2064-2070 (2009).
28. Torihata, H., et al. Irradiation up-regulates CD80 expression through two different mechanisms in spleen B cells, B lymphoma cells, and dendritic cells. Immunology 112, 219-227 (2004).
29. Ishikawa, F., et al. Irradiation up-regulates CD80 expression through induction of tumour necrosis factor-Alpha and CD40 ligand expression on B lymphoma cells. Immunology 106, 354-362 (2002).
30. Wang, L. X., et al. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses. PLoS One 8, e62924 (2013).
31. Coral, S., et al. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-Aza-2'-deoxycytidine (5-AZA-CdR). J Immunother 22, 16-24 (1999).
32. Magner, W. J., et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol 165, 7017-7024 (2000).
33. Maeda, T., Towatari, M., Kosugi, H., & Saito, H. Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 96, 3847-3856 (2000).
34. Kopp, L. M., et al. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions. Mol Immunol 54, 296-301 (2013).
35. Esteller, M., Corn, P. G., Baylin, S. B., & Herman, J. G. A gene hypermethylation profile of human cancer. Cancer Res 61, 3225-3229 (2001).
36. Nie, J., Liu, L., Li, X., & Han, W. Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors. Cancer Lett 354, 12-20 (2014).
37. Mapara, M. Y., & Sykes, M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22, 1136-1151 (2004).
38. Terunuma, H., Deng, X., Dewan, Z., Fujimoto, S., & Yamamoto, N. Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections. Int Rev Immunol 27, 93-110 (2008).
39. Plate, J. M. Advances in therapeutic vaccines for pancreatic cancer. Discov Med 14, 89-94 (2012).
40. Serrano, A., et al. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-Aza-2'-deoxycytidine treatment. Int J Cancer 94, 243-251 (2001).
41. Park, B., Yee, C., & Lee, K. M. The effect of radiation on the immune response to cancers. Int J Mol Sci 15, 927-943 (2014).
42. Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. Functions of natural killer cells. Nat Immunol 9, 503-510 (2008).
43. Cheng, M., Chen, Y., Xiao, W., Sun, R., & Tian, Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 10, 230-252 (2013).
44. Moretta, A., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19, 197-223 (2001).
45. Watzl, C. The NKG2D receptor and its ligands-recognition beyond the 'missing self ? Microbes Infect 5, 31-37 (2003).
46. Long, E. O. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 17, 875-904 (1999).